Health and Healthcare

How Analysts Changed Views on BioMarin After Earnings

Thinkstock

BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN) reported its fourth-quarter financial results after the markets closed Thursday. Investors really took to this stock and there was a favorable jump after the report. However, analysts took a slightly different perspective and cut their price targets.

The company said it had $0.40 in earnings per share (EPS) on $227.9 million in revenue, which compared to consensus estimates from Thomson Reuters of $0.99 in EPS on revenue of $224.38 million. The same period from last year had a net loss of $0.47 per share on $230.85 million in revenue.

In terms of guidance for 2016, the company expects to have a non-GAP net loss of in the range of $75 million to $100 million, as well as total revenues in the range of $1.05 billion to $1.10 million. The consensus estimates for the full year call for a net loss of $2.27 per share on $1.15 billion in revenue.

A few analysts weighed in on BioMarin after earnings:

  • JPMorgan has an Overweight rating and lowered its price target to $117 from $121.
  • Piper Jaffray has an Overweight rating and lowered its price target to $107 from $118.
  • Jefferies has a Buy rating and lowered its price target from $132 to $120.
  • RBC has an Outperform rating and lowered its price target to $125 from $155.
  • Goldman Sachs lowered its price target to $129 from $131.


So far in 2016, BioMarin has underperformed the broad markets, with the stock down 27%. Over the past 52 weeks, the stock fell 28%.

Shares of BioMarin ended last week at $80.14, with a consensus analyst price target of $127.84 and a 52-week trading range of $62.12 to $151.75.

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans  set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: are you ahead, or behind on your retirement goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With SmartAsset’s free tool, you can connect with vetted financial advisors in minutes.

Why wait? Click here to get started today!

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.